Insider Transactions in Q3 2023 at Genelux Corp (GNLX)
Insider Transaction List (Q3 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 28
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
2,289
-0.15%
|
$54,936
$24.12 P/Share
|
|
Sep 27
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
11,257
-0.74%
|
$270,168
$24.47 P/Share
|
|
Sep 26
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
29,805
-0.64%
|
$685,515
$23.67 P/Share
|
|
Sep 26
2023
|
Tony Yu VP, Clinical Trial Operations |
SELL
Open market or private sale
|
Direct |
5,200
-1.58%
|
$119,600
$23.5 P/Share
|
|
Sep 26
2023
|
Tony Yu VP, Clinical Trial Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
5,200
+4.46%
|
$31,200
$6.0 P/Share
|
|
Sep 25
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
12,458
-0.2%
|
$323,908
$26.25 P/Share
|
|
Sep 22
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
9,042
-0.29%
|
$244,134
$27.32 P/Share
|
|
Sep 21
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
7,549
-0.24%
|
$211,372
$28.36 P/Share
|
|
Sep 20
2023
|
Tony Yu VP, Clinical Trial Operations |
SELL
Open market or private sale
|
Direct |
6,000
-5.35%
|
$162,000
$27.96 P/Share
|
|
Sep 20
2023
|
Tony Yu VP, Clinical Trial Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+5.08%
|
$36,000
$6.0 P/Share
|
|
Sep 20
2023
|
Sean Ryder General Counsel |
SELL
Open market or private sale
|
Direct |
10,000
-94.59%
|
$300,000
$30.0 P/Share
|
|
Sep 20
2023
|
Sean Ryder General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+48.61%
|
$60,000
$6.0 P/Share
|
|
Sep 19
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Direct |
32,167
-87.18%
|
$836,342
$26.68 P/Share
|
|
Sep 18
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
30,292
-57.23%
|
$696,716
$23.69 P/Share
|
|
Sep 18
2023
|
John Thomas |
SELL
Open market or private sale
|
Direct |
3,334
-0.7%
|
$80,016
$24.99 P/Share
|
|
Sep 15
2023
|
John Thomas |
SELL
Open market or private sale
|
Direct |
3,333
-0.35%
|
$73,326
$22.03 P/Share
|
|
Sep 15
2023
|
Tony Yu VP, Clinical Trial Operations |
SELL
Open market or private sale
|
Direct |
10,400
-4.57%
|
$218,400
$21.93 P/Share
|
|
Sep 15
2023
|
Tony Yu VP, Clinical Trial Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
10,400
+8.19%
|
$62,400
$6.0 P/Share
|
|
Sep 14
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
25,276
-23.52%
|
$556,072
$22.04 P/Share
|
|
Sep 13
2023
|
Tony Yu VP, Clinical Trial Operations |
SELL
Open market or private sale
|
Direct |
29,800
-21.92%
|
$625,800
$21.14 P/Share
|
|
Sep 13
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
19,032
-12.47%
|
$399,672
$21.79 P/Share
|
|
Sep 13
2023
|
John W Smither |
SELL
Open market or private sale
|
Direct |
900
-11.51%
|
$18,000
$20.78 P/Share
|
|
Sep 12
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
20,265
-10.63%
|
$445,830
$22.13 P/Share
|
|
Sep 11
2023
|
John W Smither |
BUY
Grant, award, or other acquisition
|
Direct |
6,920
+46.95%
|
-
|
|
Sep 11
2023
|
John Thomas |
BUY
Grant, award, or other acquisition
|
Direct |
3,460
+0.71%
|
-
|
|
Sep 11
2023
|
James L Tyree |
BUY
Grant, award, or other acquisition
|
Direct |
3,460
+21.73%
|
-
|
|
Sep 11
2023
|
Mary Mirabelli |
BUY
Grant, award, or other acquisition
|
Direct |
3,460
+43.69%
|
-
|
|
Sep 11
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
32,351
-12.9%
|
$679,371
$21.97 P/Share
|
|
Sep 11
2023
|
Caroline Jewett Head of Quality |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+48.62%
|
-
|
|
Sep 11
2023
|
Ralph Smalling Head of Regulatory |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+45.32%
|
-
|
|
Sep 08
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
24,831
-5.54%
|
$571,113
$23.49 P/Share
|
|
Sep 07
2023
|
Aladar Szalay |
SELL
Open market or private sale
|
Indirect |
12,446
-3.72%
|
$298,704
$24.73 P/Share
|
|
Aug 30
2023
|
Tony Yu VP, Clinical Trial Operations |
SELL
Open market or private sale
|
Direct |
19,800
-12.71%
|
$475,200
$24.7 P/Share
|
|
Aug 18
2023
|
Tony Yu VP, Clinical Trial Operations |
SELL
Open market or private sale
|
Direct |
3,265
-2.05%
|
$75,095
$23.73 P/Share
|
|
Aug 18
2023
|
Joseph Cappello VP, Pharmaceutical Development |
SELL
Open market or private sale
|
Direct |
3,265
-36.28%
|
$75,095
$23.73 P/Share
|
|
Aug 18
2023
|
Sean Ryder General Counsel |
SELL
Open market or private sale
|
Direct |
328
-36.44%
|
$7,544
$23.73 P/Share
|
|
Aug 18
2023
|
Doug Samuelson Vice President, Finance |
SELL
Open market or private sale
|
Direct |
1,297
-36.03%
|
$29,831
$23.73 P/Share
|
|
Aug 18
2023
|
Ralph Smalling Head of Regulatory |
SELL
Open market or private sale
|
Direct |
935
-31.17%
|
$21,505
$23.73 P/Share
|
|
Aug 18
2023
|
Caroline Jewett Head of Quality |
SELL
Open market or private sale
|
Direct |
515
-31.21%
|
$11,845
$23.73 P/Share
|
|
Aug 18
2023
|
Thomas Zindrick President and CEO |
SELL
Open market or private sale
|
Direct |
8,349
-36.3%
|
$192,027
$23.73 P/Share
|